Ascendiant Capital Rates Outlook Therapeutics (OTLK) buy

Ascendiant Capital maintains its optimistic view on Outlook Therapeutics with a $10 price target, a 762.07% upside from the current price.

By TradeTexts Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 16, 2026, 9:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Ascendiant Capital rated Outlook Therapeutics, Inc. ($OTLK) "buy" with a $10 price target on June 11, 2026.

Since the rating, $OTLK is up 43.6% after 1 week, up 40.9% after 1 month and down 55.5% to date (from the $1.10 close on Jun 11, 2026).

OTLK Outlook Therapeutics, Inc.

$0.49 -25.76% year to date

Daily close · Oct 16, 2026

Key Points

Ascendiant Capital reiterated its buy rating on Outlook Therapeutics with a $10 price target on June 11, 2026.
Ascendiant Capital's $10 price target implies 762.07% upside from Outlook Therapeutics, Inc.'s ($OTLK) current $1.16 share price.
Outlook Therapeutics, trading near $1.12, has a market cap of $181.3 million and a 52-week high of $3.39.
Ghiath Sukhtian made significant insider purchases, while analysts maintain mixed outlooks with a mean target of $5.5.

Get $OTLK trade alerts by text

We text you when insiders, Congress or big funds trade $OTLK. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Outlook Therapeutics, Inc. alert may contain errors. Disclosures

On June 11, 2026, Ascendiant Capital reiterated its buy rating on Outlook Therapeutics, Inc. (NasdaqCM: OTLK), setting a price target of $10. Analyst Edward Woo maintains confidence in the company's potential, despite its current share price trading around $1.12.

Outlook Therapeutics, Inc. Stock Up 77.8%

Shares of NasdaqCM:OTLK traded near $1.12. Outlook Therapeutics has a market cap of approximately $181.3 million. The stock has experienced a 52-week low of $0.16 and a high of $3.39. With a beta of 0.983, the stock shows moderate volatility. The company's forward P/E ratio is not meaningful as it isn’t profitable, with a negative EPS of -1.13.

12-month forecast

$OTLK price target

Outlook Therapeutics, Inc. daily closes and this analyst's $10 target. Not advice.

Other Institutional Activity in Outlook Therapeutics

Several institutional investors have been active in Outlook Therapeutics. Armistice Capital, LLC holds 4,168,000 shares valued at about $857,774. Vanguard Capital Management LLC has 1,967,160 shares worth approximately $405,235. Geode Capital Management, LLC increased its holdings by 287,142 shares, ending with 603,606 shares valued at $124,235. Gilpin Wealth Management, LLC also added 245,962 shares, holding a total of 600,162 shares valued at $123,514. BlackRock, Inc. upped its stake by 72,929 shares to 477,471 shares, valued at $98,264.

Insider Buying and Selling at Outlook Therapeutics, Inc.

Recent insider activity includes several significant transactions. On June 2, 2026, Yezan Munther Haddadin purchased 29,000 shares at $0.83. Ghiath Sukhtian was notably active on May 28, 2026, buying 8,539,709 shares at $0.59 and selling 12,029,999 shares on the same day. On May 27, 2026, Faisal Ghiath Sukhtian acquired 122,174 shares at $0.41.

Analysts Set New Price Targets

On June 11, 2026, Ascendiant Capital maintained its buy rating on Outlook Therapeutics with a $10 price target. The consensus among analysts is a buy, with a mean price target of $5.5 based on three opinions. Other firms, such as Chardan Capital, have a hold rating with a $1 target, reflecting mixed views on the stock's potential.

About Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Iselin, New Jersey. It focuses on developing monoclonal antibodies for eye diseases, particularly an ophthalmic formulation of bevacizumab, known as ONS-5010. This product is in Phase-III trials for treating wet age-related macular degeneration. Led by CEO Mr. Robert Charles Jahr, the company collaborates with Cencora and employs 17 people.

Bottom Line

Ascendiant Capital's reaffirmation of its buy rating and $10 price target for Outlook Therapeutics highlights the firm's confidence in the company's prospects. Investors should note that 13F filings and analyst ratings are backward-looking and may not represent current positions or opinions. Tracking these changes can provide insights into institutional sentiment and stock performance expectations.